The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma

Zaydfudim, Victor M.; Feurer, Irene D.; Griffin, Marie R.; Phay, John E.

doi:10.1016/j.surg.2008.08.034

Cited by 401 publications

(293 citation statements)

References 15 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…Some studies investigating the impact of LN metastasis on the survival of PTC patients indicated that large nodal metastases (≥3 cm) in older patients (age ≥50 years), extranodal invasion, LN involvement in patients ≥45 years of age, LN metastases (N1 status) with T1-T3 status, N1b status with a carcinoma of ≥3.0 cm, a ratio of metastatic LNs to total LNs of ≥0.42, and lateral/mediastinal cervical involvement in patients ≥45 years of age were associated with a poor prognosis [3,[10][11][12][13][14][15]. Furthermore, lateral/mediastinal nodal metastasis is reported to be associated with recurrence [16].…”

Section: Discussionmentioning

confidence: 99%

Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma

Moritani

2016

Endocr J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma

Moritani

2016

Endocr J

View full text Add to dashboard Cite

“…As compared with adults, children with DTC present with more extensive disease [2,25,26]. Lymph node involvement at diagnosis is seen in 40-90% of children [2,25,26], compared with 20-50% of adults [27]. Thirdly, distant metastases, usually pulmonary, are commoner (20-30%) in children, whereas they are seen in about 2% adults [2,9,22,26,28].…”

Section: Clinical Features and Behaviourmentioning

confidence: 99%

Pediatric Thyroid Cancers: An Indian Perspective

Chaukar

Vaidya

2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Pediatric thyroid cancer is a rare entity accounting for less than 5% of all thyroid cancers. This intriguing disease is characterized by advanced presentation, coupled with frequent lymph nodal metastases and often pulmonary metastases. It perhaps exhibits a distinct biology and behaviour, because in spite of its aggressiveness, survival is extremely good. This mandates meticulous treatment decisions that are well executed, because the complications of therapy in patients with good survival may spell prolonged morbidity. Being an unusual disease, it is unlikely that level I evidence guiding the management will come forth. There have been controversies regarding management, and the current consensus comes from large prospective studies. There have been only a few studies from India detailing pediatric thyroid cancers. In the current discussion, we review the existing evidence about pediatric thyroid cancers, and try to have an Indian perspective at the problem.

show abstract

“…19 Three Surveillance, Epidemiology and End Results (SEER) registry studies found that the involvement of cervical lymph nodes metastases increases mortality in PTC patients, particularly for those older than 45 years, but it was not evident from these studies if the lymph node metastases were clinically evident or unapparent. 20,21 There are only a few prospective, randomized, controlled studies regarding PCCLND and recurrence. one of these studies analyzed the data of 181 patients with PTC, including those with stage III, or extrathyroid extension, or aggressive histology.…”

Section: Discussionmentioning

confidence: 99%

Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis

Michalaki

Bountouris

Roupas

et al. 2016

View full text Add to dashboard Cite

BAcKgrounD: The current trend in the management of low risk differentiated thyroid carcinoma is to follow less aggressive strategies. oBjEcTIVE: To assess the long-term morbidity and mortality outcomes of low-risk papillary thyroid carcinoma (pTc) patients undergoing minimal intervention. DEsIgn: we retrospectively analyzed 137 patients with low-risk pTc (stage I: n=77; stage II: n=60). of these patients, 107 (group 1) had macro-pTc and underwent near-total thyroidectomy and received postoperatively 50mci rAI. The remaining 30 patients (group 2) had micro-pTc (<1cm) and were treated only by means of near-total thyroidectomy. rEsulTs: The median follow-up for group 1 patients was 10 years (range: 3-30). At 1-year evaluation, 8 patients of group 1 had indeterminate or incomplete biochemical response, of whom 4 had also incomplete structural response to initial therapy. only 1 of 4 patients with structural incomplete response underwent cervical lymph node dissection and then received an additional dose of 100mci rAI. The remaining 7 patients received only an additional dose of 100mci rAI. These patients have been continuously followed till the present time with no recurrences or deaths (median follow-up: 17.5 years; 3-30 years). At 15 years, 2 patients of group 1 experienced biochemical recurrence and they received 100mci rAI. Three patients of group 2 experienced recurrence, with 2 receiving 50mci rAI and 1 undergoing cervical lymph node dissection with 50mci rAI. conclusIons: patients with low-risk macro-pTc treated by means of near-total thyroidectomy without pcclnD and receiving postoperatively a low dose of 50mci rAI have excellent long-term prognosis.

show abstract

The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma

Cited by 401 publications

References 15 publications

Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma

Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma

Pediatric Thyroid Cancers: An Indian Perspective

Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis

Contact Info

Product

Resources

About